Abstract

Radiation-induced gastrointestinal syndrome is a major complication and limiting factor for radiotherapy. Tumor suppressor p53 has a protective role in radiation-induced gastrointestinal toxicity. However, its underlying mechanism remains unclear. Here we report that regulating the IL12-p40/MHC class II signaling pathway is a critical mechanism by which p53 protects against radiation-induced gastrointestinal syndrome. p53 inhibits the expression of inflammatory cytokine IL12-p40, which in turn suppresses the expression of MHC class II on intestinal epithelial cells to suppress T cell activation and inflammation post-irradiation that causes intestinal stem cell damage. Anti-IL12-p40 neutralizing antibody inhibits inflammation and rescues the defects in intestinal epithelial regeneration post-irradiation in p53-deficient mice and prolongs mouse survival. These results uncover that the IL12-p40/MHC class II signaling mediates the essential role of p53 in ensuring intestinal stem cell function and proper immune reaction in response to radiation to protect mucosal epithelium, and suggest a potential therapeutic strategy to protect against radiation-induced gastrointestinal syndrome.

Radiation induced gastrointestinal syndrome is a complication of radiotherapy and the tumor suppressor p53 is implicated in protection from gastrointestinal toxicity. Here Wang and colleagues show that p53 protection against radiation-induced gastrointestinal syndrome involves intestinal stem cell function and inhibition of inflammation triggered by radiation via the IL12- p40/MHC-II axis.

Details

Title
p53 suppresses MHC class II presentation by intestinal epithelium to protect against radiation-induced gastrointestinal syndrome
Author
Wang, Jianming 1 ; Chang, Chun-Yuan 1   VIAFID ORCID Logo  ; Yang, Xue 1 ; Zhou, Fan 1 ; Liu, Juan 1 ; Bargonetti, Jill 2   VIAFID ORCID Logo  ; Zhang, Lanjing 3   VIAFID ORCID Logo  ; Xie, Ping 4   VIAFID ORCID Logo  ; Feng, Zhaohui 1   VIAFID ORCID Logo  ; Hu, Wenwei 1   VIAFID ORCID Logo 

 Rutgers University, Rutgers Cancer Institute of New Jersey, New Brunswick, USA (GRID:grid.430387.b) (ISNI:0000 0004 1936 8796) 
 Hunter College, City University of New York, Department of Biological Sciences, New York, USA (GRID:grid.257167.0) (ISNI:0000 0001 2183 6649) 
 Rutgers University, Rutgers Cancer Institute of New Jersey, New Brunswick, USA (GRID:grid.430387.b) (ISNI:0000 0004 1936 8796); Rutgers University, Department of Biological Sciences, Newark, USA (GRID:grid.430387.b) (ISNI:0000 0004 1936 8796); Penn Medicine Princeton Medical Center, Department of Pathology, Plainsboro, USA (GRID:grid.412701.1) (ISNI:0000 0004 0454 0768) 
 Rutgers University, Rutgers Cancer Institute of New Jersey, New Brunswick, USA (GRID:grid.430387.b) (ISNI:0000 0004 1936 8796); Rutgers University, Department of Cell Biology and Neuroscience, Piscataway, USA (GRID:grid.430387.b) (ISNI:0000 0004 1936 8796) 
Pages
137
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2909081108
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.